Holen Sie sich die Stockscreener-App
10.85
3.33%
0.35
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
Neumora Therapeutics Inc put volume heavy and directionally bearish - TipRanks
Commit To Buy Neumora Therapeutics At $5, Earn 105.2% Annualized Using Options - Nasdaq
(NMRA) Trading Report - Stock Traders Daily
What is HC Wainwright’s Estimate for NMRA Q1 Earnings? - Defense World
Q1 Earnings Forecast for NMRA Issued By HC Wainwright - MarketBeat
HC Wainwright Reaffirms “Buy” Rating for Neumora Therapeutics (NASDAQ:NMRA) - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Given Buy Rating at HC Wainwright - Defense World
Neumora Therapeutics (NASDAQ:NMRA) Earns Buy Rating from HC Wainwright - MarketBeat
Neumora shares retain Buy rating ahead of clinical trial results By Investing.com - Investing.com Canada
Neumora Therapeutics' SWOT analysis: stock's potential in depression treatment market - Investing.com
Stock Traders Purchase High Volume of Neumora Therapeutics Call Options (NASDAQ:NMRA) - Defense World
Point72 Asset Management L.P. Takes Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
The Manufacturers Life Insurance Company Trims Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Holdings Raised by Charles Schwab Investment Management Inc. - MarketBeat
(NMRA) Proactive Strategies - Stock Traders Daily
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by Wexford Capital LP - MarketBeat
Intech Investment Management LLC Makes New $175,000 Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - Defense World
RBC maintains $29 target on Neumora amid JNJ trial update By Investing.com - Investing.com UK
Fmr LLC Trims Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Cerity Partners LLC Purchases New Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
Head-To-Head Analysis: Neumora Therapeutics (NMRA) vs. Its Competitors - Defense World
Neumora Therapeutics' SWOT analysis: stock poised for growth amid MDD trial - Investing.com Canada
Neumora Therapeutics’ (NMRA) Outperform Rating Reiterated at Royal Bank of Canada - Defense World
Neumora Therapeutics' (NMRA) Outperform Rating Reiterated at Royal Bank of Canada - MarketBeat
Contrasting Neumora Therapeutics (NMRA) and Its Competitors - Defense World
Head-To-Head Survey: Neumora Therapeutics (NMRA) vs. Its Rivals - Defense World
Neumora Therapeutics, Inc. (NMRA): This Small-Cap Stock Is Ready To Explode - MSN
This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho - MSN
10 Best Small-Cap Stocks Ready To Explode - Insider Monkey
Financial Comparison: Neumora Therapeutics (NMRA) and Its Rivals - Defense World
HC Wainwright Issues Pessimistic Forecast for NMRA Earnings - Defense World
Analysts Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $21.67 - Defense World
Equities Analysts Set Expectations for NMRA FY2024 Earnings - Defense World
FY2024 Earnings Forecast for NMRA Issued By William Blair - MarketBeat
HC Wainwright Analysts Lower Earnings Estimates for NMRA - MarketBeat
Noteworthy Friday Option Activity: NMRA, WMT, CMRE - Nasdaq
This biotech’s stock may double on treatment for depression, says Mizuho - MarketWatch
SoftBank Group Corp.'s Strategic Reduction in Neumora Therapeuti - GuruFocus.com
Neumora Therapeutics (NASDAQ:NMRA) Announces Earnings Results, Misses Estimates By $0.06 EPS - MarketBeat
Needham & Company LLC Reiterates Buy Rating for Neumora Therapeutics (NASDAQ:NMRA) - MarketBeat
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $21.67 Average PT from Analysts - MarketBeat
Neumora Therapeutics Reports Q3 2024 Financial Results - TipRanks
Neumora Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire Inc.
Where Do Analysts Think The Neumora Therapeutics Inc (NASDAQ: NMRA) Is Going - Stocks Register
Neumora Therapeutics (NMRA) to Release Quarterly Earnings on Tuesday - Defense World
Objective long/short (NMRA) Report - Stock Traders Daily
Neumora Therapeutics downgraded to Neutral from Overweight at JPMorgan - MSN
What You Didn’t Know About Neumora Therapeutics Inc (NASDAQ: NMRA) This Week - Stocks Register
Neumora Therapeutics to Participate in Upcoming Conferences in November - The Manila Times
Neumora Therapeutics (NASDAQ:NMRA) Shares Gap DownHere's Why - MarketBeat
Neumora Therapeutics (NMRA) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Auour Investments LLC Takes $3.30 Million Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA) - MarketBeat
This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For TuesdayCognex (NASDAQ:CGNX) - Benzinga
Neumora Therapeutics (NASDAQ:NMRA) Downgraded by JPMorgan Chase & Co. to Neutral - MarketBeat
JPMorgan downgrades Neumora stock, warns of potential downside without data clarity - Investing.com UK
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):